本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/11/111 分钟阅读
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results
本地自动翻译 · 来源原始语言
摘要
Closing of the €115 million licensing transaction with SERB Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026 The first commercial patient in Australia received a living-donor kidney…
来源原始语言: PR Newswire UK — News Releases打开原始公告 →